anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The objective of this study was to investigate factors related to recurrent falls among older adults attending primary health care, considering the biopsychosocial perspective. A representative sample of 201 older adults were interviewed in three Primary Health Care units randomly selected in a city in southeastern Brazil. Outcome included self-report of two or more falls in the past 12 months. Exposures included personal and environmental aspects, according to domains of International Classification of Functioning of the World Health Organization (ICF-WHO). Recurrent falls were reported by 24.4% of the participants. Associations with depressive symptoms (p = .003), having osteoporosis (p = .031), chronic musculoskeletal pain (p = .020), frailty (p = .013), sleep satisfaction (p < .001), and functional status (p < .001) were found. In logistic regression models, cognitive status, musculoskeletal pain, and functional status were predictors of recurrent falls; however, only sleep satisfaction remained significant in the final model. Strategies aimed at preventing recurrent falls in primary health care should consider assessments and interventions targeting sleep aspects among older adults.
This study aimed to investigate what factors determine freedivers' maximal static apnea dive time. We correlated some physical/physiological factors with male freedivers' maximum apnea diving duration. Thirty-six experienced male freedivers participated in this study. The divers participated in two days of the experiments. On the first day, apnea diving time, blood oxygen saturation (SpO2), heart rate (HR), blood pressure (BP), stress index, and blood parameters were measured before, during, and after the apnea diving in the pool. On the second day, body composition, lung capacity, resting and maximal oxygen consumption (VO2max), and the Wingate anaerobic power were measured in the laboratory. The data were analyzed with Pearson's Correlation using the SPSS 22 program. The correlation coefficient (R) of determination was set at 0.4, and the level of significance was set at p <0.05. There were positive correlations of diving experience, maximum SpO2, and lung capacity with the maximum apnea time R>0.4, P<0.05). There were negative correlations of BMI, body fat percentage, body fat mass, minimum SpO2, stress index, and total cholesterol with the maximum apnea diving time (R>-0.4, P<0.05). No correlations of age, height, weight, fat-free mass, skeletal muscle mass, HR, BP, blood glucose, beta- hydroxybutyrate, lactate, and hemoglobin levels with the maximum apnea diving time were observed (R<0.4, P>0.05). It is concluded that more experience in freediving, reduced body fat, extended SpO2 range, and increased lung capacity are the performance predictors and beneficial for freedivers to improve their maximum apnea diving performance.
In recent years, we have witnessed both artificial intelligence obtaining remarkable results in clinical decision support systems (CDSSs) and explainable artificial intelligence (XAI) improving the interpretability of these models. In turn, this fosters the adoption by medical personnel and improves trustworthiness of CDSSs. Among others, counterfactual explanations prove to be one such XAI technique particularly suitable for the healthcare domain due to its ease of interpretation, even for less technically proficient staff. However, the generation of high-quality counterfactuals relies on generative models for guidance. Unfortunately, training such models requires a huge amount of data that is beyond the means of ordinary hospitals. In this paper, we therefore propose to use federated learning to allow multiple hospitals to jointly train such generative models while maintaining full data privacy. We demonstrate the superiority of our approach compared to locally generated counterfactuals. Moreover, we prove that generative models for counterfactual generation that are trained using federated learning in a suitable environment perform only marginally worse compared to centrally trained ones while offering the benefit of data privacy preservation. Finally, we integrate our method into a prototypical CDSS for treatment recommendation for sepsis patients, thus providing a proof of concept for real-world application as well as insights and sanity checks from clinical application.
The invention provides a polypeptide, the molecular weight is 3321.6Da, and the amino acid sequence is shown in SEQ ID NO. 1. The present invention also provides six kinds of derivatives of the polypeptide. The polypeptide and the derivatives thereof provided by the invention have high-efficiency broad-spectrum antibacterial effects such as gram-positive bacteria and gram-negative bacteria (particularly have good killing effect on anaerobic propionibacterium acnes resisting clindamycin), fungi and saccharomycetes, and high activity (the concentration for killing propionibacterium acnes in vitro can be only 0.125 mg/L). Can be used for preparing products for controlling microbial and fungal infection and resisting inflammation, wherein the products comprise external disinfectants, antibacterial agents, wound protection or infection prevention dressings, acne treatment medicines, skin care products, cosmetics and the like. The polypeptide is designed and synthesized based on the fragment containing the tryptophan bromide of the sea urchin, and has stronger effects of inhibiting or killing bacteria and resisting inflammation and better stability. Can be used as antibiotic substitute.
This is an Intervention Model where all patients who are identified/confirmed candidates for microfracture surgery will be enrolled to receive the microfracture surgery (standard of care). Ten (10) patients will be randomized to receive the microfracture surgery (standard of care).
BACKGROUND: Several indexes based on clinical and laboratory tests to identify frailty and to predict mortality have been produced. Only two studies, mixing clinical and laboratory parameters were made about a frailty index made of laboratory tests (FI-Lab) and mortality in older patients hospitalized for COVID-19. The aim of this study was to explore the accuracy and precision of an FI-Lab constructed with some common bio-humoral tests and mortality in a cohort of patients hospitalized for COVID-19.
METHODS: The FI-Lab was constructed using 40 different bio-humoral tests during the first four days of hospitalization, with a score from 0 to 1. The association between FI-Lab and mortality was assessed using a multivariate Cox's regression analysis, reported as hazard ratios (HRs) and 95% confidence intervals (CIs). The accuracy of the FI-Lab was reported as area under the curve (AUC) and the precision with the C-Index.
RESULTS: 376 patients (mean age: 65 years; 53.7% males) were initially included. During the follow-up period, 41 deceased. After adjusting for five different factors, an FI-Lab value >0.54, the median value of our cohort, was associated with a relative risk about five times greater than lower values. Modeling FI-LAB as a continous variable, each increase in 0.01 points was associated with an increased risk in mortality of 8.4% (HR=1.084; 95%CI: 1.039-2.044). The FI-Lab was highly accurate (AUC=0.91; 95%CI: 0.87-0.95) and precise (C-Index=0.81) in predicting death.
CONCLUSIONS: A simple index based on common laboratory tests can be used to predict mortality among older people hospitalized for COVID-19.
OXYGEN, COMPRESSED USP UN 1072

OXYGEN 2 17033 (R-K14) 118841

WARNING: For emergency use only when administered by properly trained personnel for oxygen deficiency and resuscitation. For all other medical applications, Rx only. Uninterrupted use of high concentrations of oxygen over a long duration, without monitoring its effect on oxygen content of arterial blood, may be harmful. Do not attempt to use on patients who have stopped breathing unless used in conjunction with resuscitative equipment. DANGER: MAY CAUSE OR INTENSIFY FIRE; OXIDIZER. CONTAINS GAS UNDER PRESSURE; MAY EXPLODE IF HEATED. Do not handle until all safety precautions have been read and understood. Keep and store away from clothing and other combustible materials. Keep valves and fittings free from grease and oil. Use and store only outdoors or in a well-ventilated place. In case of fire: Stop leak if safe to do so. Use a backflow preventive device in the piping. Use only with equipment of compatible materials of construction and rated for cylinder pressure. Use only with equipment cleaned for oxygen service. Open valve slowly. Close valve after each use and when empty. Protect from sunlight when ambient temperature exceeds 52°C (125° F). Read and follow the Safety Data Sheet (SDS) before use. CAS 7782-44-7 DO NOT REMOVE THIS PRODUCT LABEL.

CONTENTS:

LTRS: ___

CU.FT. ___

KENT WELDING SUPPLY

66485 Hwy 51. •Fluker, LA 70436

985-748-9418
The present invention relates to a pharmaceutical composition for preventing or treating neuroinflammatory diseases, that contains, as an active ingredient, a mixed extract of Rhemannia glutinosa Liboschitz var. purpurea Makino, Dioscorea japonica Thunb., ornus officinalis Sieb. et Zucc., Poria cocos Wolf, Gastrodia elata Blume, Morus alba Linne, Lycium chinense Miller, Schisandra chinensis (Turcz.) Baillon, Cervus elaphus sibericus, and Hominis Placenta. A pharmaceutical composition for preventing or treating neuroinflammatory diseases according to the present invention can reduce inflammation and oxidative damage in brain tissue caused by endotoxins by regulating the function of Sirt6, which is an epigenetic factor. In particular, the pharmaceutical composition can normally restore the glutathione oxidation/antioxidation system of brain tissue based on antioxidant efficacy and can effectively regulate the Nrf2/Ho-1 axis, which exhibits the representative mechanism of antioxidant efficacy.
Dysregulated transplacental lipid transfer and fetal-placental lipid metabolism affect birthweight, as does maternal hyperglycemia. As the mechanisms are unclear, we aimed to identify the lipids in umbilical cord plasma that were most associated with birthweight. Seventy-five Chinese women with singleton pregnancies recruited into the GUSTO mother-offspring cohort were selected from across the glycemic range based on a mid-gestation 75 g oral glucose tolerance test, excluding pre-existing diabetes. Cord plasma samples collected at term delivery were analyzed using targeted liquid-chromatography tandem mass-spectrometry to determine the concentrations of 404 lipid species across 17 lipid classes. The birthweights were standardized for sex and gestational age by local references, and regression analyses were adjusted for the maternal age, BMI, parity, mode of delivery, insulin treatment, and fasting/2 h glucose, with a false discovery-corrected p < 0.05 considered significant. Ten lysophosphatidylcholines (LPCs) and two lysophosphatidylethanolamines were positively associated with the birthweight percentiles, while twenty-four triacylglycerols were negatively associated with the birthweight percentiles. The topmost associated lipid was LPC 20:2 [21.28 (95%CI 12.70, 29.87) percentile increase in the standardized birthweight with each SD-unit increase in log10-transformed concentration]. Within these same regression models, maternal glycemia did not significantly associate with the birthweight percentiles. Specific fetal circulating lysophospholipids and triacylglycerols associate with birthweight independently of maternal glycemia, but a causal relationship remains to be established.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to preparation used for treatment of patients with respiratory allergic vasomotor diseases. Method involves administration of effective amount of ready pharmaceutical aerosol form of reparative-regenerative preparation based on adder venom in nasopharynx. Preparation is dosed in quantitative and temporary ratio and patient is treated up to achievement of stable therapeutic effect based on tolerance and response of patient. Invention relates to also method of making the preparation and its medicinal form. EFFECT: improved method of making, broadened functional possibilities of drug using. 5 cl, 3 ex
Subjects received riociguat film coated immediate-release (IR) tablet 3 times a day (tid) with or without food at a starting dose of 1.0 milligram (mg) and increased by 0.5 mg increments at 2-weekly intervals to a maximum of 2.5 mg tid, until Week 8 (titration phase). An optimal dose was determined based on systolic blood pressure (SBP) and well-being. Thereafter, riociguat continued at the optimal individual dose until Week 24 (Main phase). Dose reductions or stop of study medication for safety reasons were allowed at any time. Increases or re-increases in 0.5 mg steps (maximum dose 2.5 mg) were possible at the investigator's discretion weighing the benefit with potential risks implied. Subjects were offered participation in EDSP and received riociguat 2.5 mg film coated IR tablet 3 tid with or without food for 18 months or until reimbursement.
Urothelial carcinoma are tumors originating from the urothelial cells that line the bladder, renal pelvis, ureter, and urethra. Each year, bladder cancer (BC) accounts for 3.0% of global cancer diagnoses, with more than 570,000 new cases diagnosed and 2.1% of new deaths, with more than 210,000 deaths worldwide. In Latin America, BC placed the 10th and 9th positions in the incidence of cancer in Argentina and Brazil, respectively, and both countries have BC as the 5th most frequent cancers among males excluding non-melanoma skin cancer. 2-4 Among men, BC is the 6th most common cancer and the 9th leading cause of cancer death. Incidence and mortality in males are approximately four times higher compared to women with BC globally. In 2020, Argentina and Brazil reported over 3,700 and 15,800 new cases of BC, respectively. The 5-year prevalence at all ages of 11,401 (25 per 100,000) in Argentina and 43,545 (20 per 100,000) in Brazil. Besides male population, other risk factors for BC include prevalence of tobacco smoking, infection with Schistosoma haematobium, occupational exposures to organic solvents, and arsenic contamination in drinking water. 2,5 First-line standard of care for patients with advanced or metastatic urothelial cancer is a platinum-based chemotherapy regimen; however, the median OS in patients treated with Cisplatin-based chemotherapy is only 12-14 months, approximately. Besides, most patients with advanced or metastatic urothelial cancer commonly experience disease progression within 9 months after initiation of treatment
Sexual dimorphism among mammals includes variations in the pain threshold. These differences are influenced by hormonal fluctuations in females during the estrous and menstrual cycles of rodents and humans, respectively. These physiological conditions display various phases, including proestrus and diestrus in rodents and follicular and luteal phases in humans, distinctly characterized by varying estrogen levels. In this study, we evaluated the capsaicin responses in male and female mice at different estrous cycle phases, using two murine acute pain models. Our findings indicate that the capsaicin-induced pain threshold was lower in the proestrus phase than in the other three phases in both pain assays. We also found that male mice exhibited a higher pain threshold than females in the proestrus phase, although it was similar to females in the other cycle phases. We also assessed the mRNA and protein levels of TRPV1 in the dorsal root and trigeminal ganglia of mice. Our results showed higher TRPV1 protein levels during proestrus compared to diestrus and male mice. Unexpectedly, we observed that the diestrus phase was associated with higher TRPV1 mRNA levels than those in both proestrus and male mice. These results underscore the hormonal influence on TRPV1 expression regulation and highlight the role of sex steroids in capsaicin-induced pain.
Some embodiments of the invention include compounds of the invention (e.g., compounds of formula (I)) including, but not limited to, conjugates comprising FK-506 and an ascomycin. Other embodiments include compositions (e.g., pharmaceutical compositions) comprising a compound of the invention. Other embodiments of the invention include compositions for treating, for example, certain diseases using the compounds of the invention. Some embodiments include methods of administration and treatment using the compounds of the invention (e.g., in a composition or pharmaceutical composition). Other embodiments include methods of making the compounds of the present invention. Other embodiments of the invention are also discussed herein.
1417527 Sustained release device ALZA CORP 20 Dec 1973 [27 Dec 1972 (3)] 59111/73 Headings A5B, A5E and A5R [Also in Division C5] A sustained release drug or disinfectant dispensing device comprises an active agent dispersed in a body of hydrophobic poly(carboxylic acid) having one carboxyl hydrogen atom per 8 to 22 carbon atoms. In an aqueous environment of pH 6 to 7, the insoluble poly- (carboxylic acid) is slowly hydrolysed to soluble salt with gradual release of the active agent. Poly(carboxylic acids) specified are copolymers of ethylene and mono-n-butyl, n-pentyl, nhexyl, n-heptyl, n-octyl or n-dodecyl maleate, vinyl methyl ether and ethyl, isopropyl, n-butyl or n-pentyl maleate, n-butyl acrylate and methacrylic acid, N-vinyl pyrrolidone and n-hexyl maleate or n-decyl maleate, n-butyl acrylate and acrylic acid, styrene and monoethyl maleate, n-butyl acrylate, acrylic acid and methacrylic acid and n-pentyl acrylate, n-hexyl methacrylate and acrylic acid. The device may comprise a plurality of layers-Fig. 2-each including a different active ingredient. In one embodiment, the device is adapted for insertion in the ocular cavity of a mammal and the active agent is hydrocortisone, a pilocarpine salt or chloramphenicol. In another embodiment, the device is adapted (Figure 3) for insertion in the uterine cavity and the active agent is a progesterone or prostaglandin. Such devices may be shaped as in Figs. 6 and 7. In example 8, a toilet cleaner and disinfectant comprise a copolymer of n-butyl acrylate and methacrylic acid, dodecyl benzene sulphonate, benzalkonium chloride and colouring. The device may be contained in a foraminous holder for suspension in a toilet cistern-Fig. 4,
Treatment group A: oral SHR7280 tablets; 300mg bid p.o.; Treatment group B: oral SHR7280 tablets; 200mg bid p.o.; Treatment group C: oral SHR7280 tablets; 200mg qd p.o.; Treatment group D: oral SHR7280 tablets; 400mg bid p.o.; as an alternative.
The utility model discloses a nasal breath expanded patch. An upper patch layer is composed of two symmetrical upper paranasal patches layers and an upper nose-bridge patch layer and the lower patch layer is composed of two symmetrical lower paranasal patches layers which correspond to  the upper patch layer and an lower nose-bridge patch layer. A cushion disk is arranged between the upper patch layer and the lower patch layer. The corresponding parts of the upper patch layer and the lower patch layer are connected accordingly; an interval is arranged between the paranasal patch layer and the nose-bridge patch layer and liniment holes for drugs are arranged on the location on the lower paranasal patch layer and corresponding to the acupuncture point of the nosewing. The nasal breath expanded patch has simple structure and convenient use, can efficiently expand the breath of the nasal cavity, increase the respiratory capacity of the nasal cavity and is applicable to the noses with different shapes. Moreover, the drugs in the liniment holes and heated by the human skin slightly permeate through acupuncture point to cure the nasal diseases and make the breath unblocked.
Participants will receive 1 oral tablet of budesonide MMX 9 mg for 56 days. Additionally, participants will continue to receive the same dose of their existing oral 5-ASA medication from their treating physician.
Opossum whole serum exhibits a life saving property by neutralizing the lethality of venoms from all major families of poisonous snakes, and therefore an injection of Opossum serum can used as a novel treatment for many types of envenomation. Preferably, the injectable treatment for envenomation should be a composition obtained from the fraction of Opossum whole serum which contains the lethal toxin neutralizing factor, i.e. the so called "natural LTNF", in purity. A method is given for the manufacture of a lethal toxin neutralizing factor from the serum of an opossum (Didelphis virginiana) serum, by fractionating the opossum serum and isolating this select fraction from the plurality of fractions having an N terminal amino acid sequence given by SEQ ID No: 1. A short peptide was synthesized having SEQ ID No: 1. The synthetic peptide having sequence SEQ ID No: 1 shows lethal toxin neutralizing activity similar to the natural LTNF from opossum or mongoose sera. The synthetic LTNF also has life saving utility.
A non-aqueous liquid cleaning composition for applicators used for applying non-aqueous hair removal compositions to the skin. The composition includes a solubilizing oil effective for solubilizing the non-aqueous hair removal composition, e.g., mineral oil, and an effective antibacterial amount of an antibacterial agent, e.g., triclosan. The composition may also include fragrances and additional bacteriocides, e.g., phenoxyethanol. When the applicator is contacted with the heated cleaning composition any hair removal composition and bacteria on the applicator are removed therefrom and the applicator is ready for reuse. It is preferred to use surgical stainless steel applicators. Also provided are methods of using these compositions and kits containing, among other items, such compositions and applicators.
The invention relates to the use of derivatives of E-type prostaglandins as EP2 agonists, in general, and, in particular as ocular hypotensives. The PGE  derivatives used in accordance with the invention are represented by the formula (I): wherein the hatched segment represents an .alpha. bonds, the solid triangle represents a .beta. bond, the wavy segments represent .alpha.  or .beta. bond, dashed lines represent a double bond or a single bond, X is selected from the group consisting of hydrogen and halogen radicals, R3 is heteroaryl or a substituted heteroaryl radical, R1 and R2 are independently selected from the group consisting of hydrogen or a lower alkyl radical having up to six carbon atoms, or a lower acyl radical having up to six carbon atoms, R is selected from the group consisting of CO2R4, CONR42, CH2OR4, CONR4SO2R4, P(O)(OR4) and formula (II), wherein R4 is selected from the group consisting of H, phenyl and lower alkyl having from one to six carbon atoms and n is 0 or an integer of from 1 to 4.